As far as which meeting, I will have to get more clarification from KK @ undisclosed Pharma to confirm. I am not the one who works at this "Pharmaceutical" company.
But from what I was told by her, the meeting would be taking place the SAME WEEK....as the upcoming FDA meeting. I felt the information was graciously provided and did not feel it was necessary at the time to ask her specifically whether she meant the FDA meeting to go over HIV Mono on the books, or the Prosta meeting in Aug. I, at the time, assumed she was referring to the most nearing FDA meet, though as you pointed out, likely the intent was regarding the upcoming HIV meeting.
The Big "Pharma" meet that was scheduled with Cytodyn has been on the books since June. Despite everyone's hope's with various indications like TnBC, colorectal, NASH, the 1 Big pharma in particular does not have faith in those indications making it past Phase 2. Even if Leronlimab works as described in HIV, as far as antagonizing CCR5 receptors, the fact that certain cancers have specificity toward CCR5 receptors doesn't mean cancer cells stop metastasizing. Cancers develop when the mutated cells are prohibited from continuing through the cell cycle. Even with correlation of metastasis to the CCR5 receptor, the cancers AT BEST CASE SCENARIO, will allow for a longer period of remission, before the cancer reemerges. THERE IS NOT 1 PATHWAY for cancer. It would be nice if life was that simple, by blocking 1 pathway and everything is solved.
These are the beliefs per my conversation with KK, not my own. I am personally a believer that Leronlimab may be efficacious in "Certain Cancers." Though its success in that realm is more dependent on the necessity for testing out on slower growing cancers. Plus getting someone in Stage 4 sounds nice, but the effect would at best only make a negligible difference in Stages 1 & 2.
With that being said, the Big Pharma company is looking at Cytodyn solely for the scope of HIV. Combo approval would be two fold benefit. 1) limiting loss of revenue for current lines of combo drugs approved, and 2) currently in process of converting at least 1 currently approved combo only drug to an injectable which could be paired with Leronlimab. I'm presently positioned nicely with Cydy, with the bulk of my shares at $0.37 and $0.38, and a small portion I never sold around $0.49. Nothing is guaranteed KK told me. Obviously, there are multiple variations of different offers that will be laid out. And you can't forget about possibility of an attempt for a hostile takeover, which would be more advantageous price wise, though that route would only benefit if after 1st approval. In the end, OFFERS WILL BE MADE, that is for sure. That doesn't mean Cytodyn will accept the terms of those offers. So we may still be left empty handed if Cydy chooses to attempt on their own. But we shall see soon enough.
But from what I was told by her, the meeting would be taking place the SAME WEEK....as the upcoming FDA meeting. I felt the information was graciously provided and did not feel it was necessary at the time to ask her specifically whether she meant the FDA meeting to go over HIV Mono on the books, or the Prosta meeting in Aug. I, at the time, assumed she was referring to the most nearing FDA meet, though as you pointed out, likely the intent was regarding the upcoming HIV meeting.
The Big "Pharma" meet that was scheduled with Cytodyn has been on the books since June. Despite everyone's hope's with various indications like TnBC, colorectal, NASH, the 1 Big pharma in particular does not have faith in those indications making it past Phase 2. Even if Leronlimab works as described in HIV, as far as antagonizing CCR5 receptors, the fact that certain cancers have specificity toward CCR5 receptors doesn't mean cancer cells stop metastasizing. Cancers develop when the mutated cells are prohibited from continuing through the cell cycle. Even with correlation of metastasis to the CCR5 receptor, the cancers AT BEST CASE SCENARIO, will allow for a longer period of remission, before the cancer reemerges. THERE IS NOT 1 PATHWAY for cancer. It would be nice if life was that simple, by blocking 1 pathway and everything is solved.
These are the beliefs per my conversation with KK, not my own. I am personally a believer that Leronlimab may be efficacious in "Certain Cancers." Though its success in that realm is more dependent on the necessity for testing out on slower growing cancers. Plus getting someone in Stage 4 sounds nice, but the effect would at best only make a negligible difference in Stages 1 & 2.
With that being said, the Big Pharma company is looking at Cytodyn solely for the scope of HIV. Combo approval would be two fold benefit. 1) limiting loss of revenue for current lines of combo drugs approved, and 2) currently in process of converting at least 1 currently approved combo only drug to an injectable which could be paired with Leronlimab. I'm presently positioned nicely with Cydy, with the bulk of my shares at $0.37 and $0.38, and a small portion I never sold around $0.49. Nothing is guaranteed KK told me. Obviously, there are multiple variations of different offers that will be laid out. And you can't forget about possibility of an attempt for a hostile takeover, which would be more advantageous price wise, though that route would only benefit if after 1st approval. In the end, OFFERS WILL BE MADE, that is for sure. That doesn't mean Cytodyn will accept the terms of those offers. So we may still be left empty handed if Cydy chooses to attempt on their own. But we shall see soon enough.
1
2
